Karachi, Otsuka Pakistan Limited informed Pakistan Stock Exchange that the Board of the Company discussed the possibility for IV Solutions 1000 mL and Glass Bottles manufacturing facility (Line-II) to be upgraded to improve in accordance with GMP compliance. The entire project expenses estimated up to Rs. 200 million (Pak Rupees Two Hundred Million) and will be completed by March 2023. All the cost of this project will be utilized from overdraft facilities available with bankers of the Company.
Otsuka Pakistan Limited was incorporated in Pakistan as a public limited company and commenced commercial production of Intravenous Solutions in September 1989 at its factory in Hub, Baluchistan.
The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan. Therapeutic Drugs are Otsuka Pakistan’s second line of business; currently consist of Pletaal and Mucosta which are being imported in finished form from Korea.
The total numbers of shares are 12,100,000. The Earnings per share is 7.53 in 2020 which was (14.49) in 2019. The Profit after Taxation is 91,066,000 in 2020 which was 175,348,000 in 2019.